Boston Scientific Corp (BSX)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 70.82% | 90.87% | 90.01% | 90.06% | 94.57% | 71.46% | 72.64% | 72.94% | 70.34% | 69.22% | 68.98% | 67.20% | 67.49% | 69.66% | 70.82% | 72.88% | 73.63% | 73.72% | 73.66% | 73.23% |
| Operating profit margin | 16.77% | 20.57% | 17.65% | 17.35% | 17.87% | 11.79% | 12.46% | 11.26% | 10.31% | 9.57% | 4.39% | 1.47% | -0.84% | 0.82% | 6.82% | 10.78% | 14.67% | 16.21% | 16.72% | 17.00% |
| Pretax margin | 14.20% | 18.36% | 15.12% | 14.84% | 12.94% | 7.15% | 9.44% | 7.89% | 9.27% | 8.87% | 2.59% | -0.49% | -3.66% | -47.27% | -43.83% | -38.06% | -34.13% | 5.11% | 9.00% | 11.18% |
| Net profit margin | 11.39% | 12.20% | 9.34% | 9.56% | 8.15% | 5.39% | 7.56% | 7.04% | 8.95% | 7.92% | 2.86% | -0.24% | -3.70% | -5.27% | -2.38% | 0.65% | 4.65% | 6.12% | 9.43% | 13.69% |
Boston Scientific Corp. has shown consistent improvement in its profitability ratios over the past quarters. The gross profit margin has been relatively stable, ranging between 68.81% and 69.49% in the last eight quarters. This indicates efficient cost management and pricing strategies in their operations.
The operating profit margin has also been on an upward trend, reflecting the company's ability to control operating expenses and generate operating income effectively. The consistent increase from 15.71% to 16.97% indicates effective operational efficiency.
The pretax margin has shown significant improvement, increasing from 6.86% to 13.95% over the past eight quarters. This signals improved profitability before considering taxes, demonstrating better financial management and operational performance.
Net profit margin, which reflects the company's overall profitability after all expenses have been considered, has also seen a consistent rise, increasing from 4.75% to 11.03%. This suggests strong financial performance and effective cost control measures, resulting in increased net income for the company.
Overall, Boston Scientific Corp. has demonstrated improved profitability across its different profit margin ratios, indicating effective cost management, operational efficiency, and enhanced financial performance over the past two years.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 6.67% | 6.35% | 5.43% | 5.27% | 5.08% | 4.47% | 4.52% | 4.00% | 3.72% | 3.35% | 1.53% | 0.47% | -0.26% | 0.26% | 2.17% | 3.73% | 4.97% | 6.08% | 6.71% | 6.89% |
| Return on assets (ROA) | 4.53% | 3.77% | 2.87% | 2.91% | 2.32% | 2.04% | 2.75% | 2.50% | 3.23% | 2.77% | 0.99% | -0.07% | -1.15% | -1.67% | -0.76% | 0.23% | 1.57% | 2.29% | 3.78% | 5.55% |
| Return on total capital | 12.15% | 11.44% | 10.02% | 9.72% | 9.38% | 8.09% | 8.44% | 7.74% | 7.21% | 6.49% | 2.99% | 0.92% | -0.52% | 0.51% | 4.28% | 8.14% | 10.94% | 16.78% | 17.32% | 17.76% |
| Return on equity (ROE) | 8.25% | 6.79% | 5.30% | 5.36% | 4.28% | 3.70% | 5.12% | 4.84% | 6.26% | 5.37% | 1.94% | -0.15% | -2.30% | -3.30% | -1.49% | 0.49% | 3.47% | 6.33% | 9.76% | 14.31% |
The profitability ratios of Boston Scientific Corp. have shown a generally positive trend over the quarters analyzed.
1. Operating return on assets (Operating ROA) has been relatively stable, ranging from 6.00% to 6.88% over the past eight quarters. This indicates that the company has been effective in generating operating income relative to its total assets.
2. Return on assets (ROA) has shown an increasing trend, improving from 1.87% in Q3 2022 to 4.47% in Q4 2023. This suggests that Boston Scientific Corp. has been more efficient in generating profits from its total assets.
3. Return on total capital has consistently remained above 7.39% in the time period analyzed. This indicates that the company has been successful in generating returns for both equity and debt holders.
4. Return on equity (ROE) has also shown a positive trend, with an increase from 3.38% in Q3 2022 to 8.14% in Q4 2023. This indicates that the company has been effectively utilizing its equity to generate profits for shareholders.
Overall, the profitability ratios of Boston Scientific Corp. demonstrate improving performance and efficiency in utilizing its assets and capital to generate returns for both equity and debt holders.
See also:
Boston Scientific Corp Profitability Ratios (Quarterly Data)